Equities

Fusion Antibodies PLC

FAB:LSE

Fusion Antibodies PLC

Health CareHealth Care Providers
  • Price (GBX)16.00
  • Today's Change0.75 / 4.92%
  • Shares traded629.92k
  • 1 Year change107.79%
  • Beta2.1450
Data delayed at least 20 minutes, as of Feb 06 2026 16:18 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Fusion Antibodies PLC grew revenues 72.98% from 1.14m to 1.97m while net income improved from a loss of 2.23m to a smaller loss of 1.71m.
Gross margin22.06%
Net profit margin-91.92%
Operating margin-95.55%
Return on assets-87.84%
Return on equity-164.37%
Return on investment-137.88%
More ▼

Cash flow in GBPView more

In 2025, cash reserves at Fusion Antibodies PLC fell by 840.00k. Cash Flow from Financing totalled 529.00k or 26.92% of revenues. In addition the company used 1.36m for operations while cash used for investing totalled 5.00k.
Cash flow per share-0.013
Price/Cash flow per share--
Book value per share0.0064
Tangible book value per share0.0064
More ▼

Balance sheet in GBPView more

Fusion Antibodies PLC has a Debt to Total Capital ratio of 34.83%, a higher figure than the previous year's 0.85%.
Current ratio1.80
Quick ratio1.45
Total debt/total equity0.5344
Total debt/total capital0.3483
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.